istock-518308224_leventince
leventince / iStockphoto.com
4 July 2018Americas

LSIPR 50 2018: It’s not like selling cars

Managing and licensing the IP portfolio of a biomedical research centre as prestigious as the Broad Institute of MIT and Harvard may come with any number of challenges, but for Issi Rozen there is one key question he tackles in his day-to-day work as chief business officer: how can the Broad’s proprietary technology have the maximum impact possible, in a responsible way?

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
5 March 2026   The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.
Americas
5 March 2026   Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.
Americas
4 March 2026   With an increase in ‘hallucinated’ case law cited as evidence in courts globally, what can legal practitioners—as well as providers of AI tools and platforms—do to help safeguard against this? Sarah Speight finds out.